After being all-but written off a year ago, AstraZeneca’s anifrolumab has been reborn with new data that suggest it could help to end a drought in treatments for autoimmune disease systemic ...

Saphnelo (anifrolumab) is the first biologic drug for SLE to be approved in Europe that is not restricted to patients with a high degree of disease activity, according to AZ, which also notes it ...

Past research in mice has shown that injection of antibodies linked to NPSLE manifestations induced olfactory deficit and that these antibodies can bind and penetrate cells in limbic areas of the ...